Skip to main content
. 2017 Dec 16;9(2):2076–2085. doi: 10.18632/oncotarget.23330

Figure 1.

Figure 1

Comparison of the respective mutational spectrum detected by targeted sequencing of both archived FFPE tumor tissue material, taken at time-point of first diagnosis, and ctDNA, isolated from blood plasma at baseline, prior to initiation of the respective therapy line, for (A) therapy naïve patients and (B) pretreated patients.